62.06
前日終値:
$62.03
開ける:
$61.83
24時間の取引高:
1.21M
Relative Volume:
0.76
時価総額:
$11.25B
収益:
$2.75B
当期純損益:
$322.29M
株価収益率:
37.16
EPS:
1.67
ネットキャッシュフロー:
$300.88M
1週間 パフォーマンス:
-1.46%
1か月 パフォーマンス:
+2.99%
6か月 パフォーマンス:
-6.03%
1年 パフォーマンス:
-24.72%
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
名前
Biomarin Pharmaceutical Inc
セクター
電話
(415) 506-6700
住所
105 DIGITAL DRIVE, NOVATO, CA
BMRN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BMRN
Biomarin Pharmaceutical Inc
|
62.06 | 11.25B | 2.75B | 322.29M | 300.88M | 1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-24 | アップグレード | Oppenheimer | Perform → Outperform |
2024-11-15 | 開始されました | Wolfe Research | Outperform |
2024-10-30 | ダウングレード | William Blair | Outperform → Mkt Perform |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-08-20 | アップグレード | Bernstein | Mkt Perform → Outperform |
2024-05-17 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-05-14 | 開始されました | Evercore ISI | Outperform |
2023-11-15 | 開始されました | Wells Fargo | Overweight |
2023-10-23 | アップグレード | Bernstein | Underperform → Mkt Perform |
2023-09-28 | 開始されました | Raymond James | Mkt Perform |
2023-09-18 | 開始されました | UBS | Buy |
2023-07-27 | 開始されました | Scotiabank | Sector Perform |
2023-07-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2023-06-14 | 再開されました | Credit Suisse | Outperform |
2023-03-21 | 開始されました | Bernstein | Underperform |
2023-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
2023-02-21 | 開始されました | Citigroup | Neutral |
2023-01-30 | 開始されました | BMO Capital Markets | Market Perform |
2023-01-18 | 開始されました | Canaccord Genuity | Hold |
2022-10-31 | アップグレード | Oppenheimer | Perform → Outperform |
2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
2022-06-13 | 再開されました | Wedbush | Neutral |
2022-04-25 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-11-22 | アップグレード | William Blair | Mkt Perform → Outperform |
2021-10-07 | 再開されました | Jefferies | Buy |
2021-09-09 | アップグレード | Stifel | Hold → Buy |
2021-06-04 | 再開されました | Robert W. Baird | Outperform |
2021-04-26 | 再開されました | Credit Suisse | Outperform |
2021-03-04 | 再開されました | Guggenheim | Buy |
2021-03-01 | アップグレード | Evercore ISI | In-line → Outperform |
2020-08-20 | ダウングレード | Citigroup | Buy → Neutral |
2020-08-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
2020-08-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2020-08-19 | ダウングレード | Stifel | Buy → Hold |
2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-07-06 | 繰り返されました | Citigroup | Buy |
2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
2020-01-24 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2019-11-27 | アップグレード | Barclays | Equal Weight → Overweight |
2019-11-12 | 開始されました | SunTrust | Buy |
2019-10-17 | 再開されました | BofA/Merrill | Buy |
2019-05-23 | 再開されました | Citigroup | Buy |
2019-04-09 | 再開されました | Raymond James | Outperform |
2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2018-12-14 | 開始されました | Wolfe Research | Outperform |
2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
2018-08-07 | 繰り返されました | Stifel | Buy |
2018-08-03 | 繰り返されました | Stifel | Buy |
すべてを表示
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know - Benzinga
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - Insider Monkey
Biomarin Pharmaceutical (BMRN) Price Target Lowered by Citigroup - GuruFocus
BioMarin Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Cantor maintains BioMarin stock overweight with $90 target By Investing.com - Investing.com South Africa
BioMarin's First-Quarter Earnings & Sales Beat Estimates - TradingView
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
Cantor maintains BioMarin stock overweight with $90 target - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
BioMarin’s Strong Q1 2025 Performance and Growth Outlook - TipRanks
BioMarin Pharmaceutical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioMarin (BMRN) Reports Strong Q1 2025 Growth and Strategic Adva - GuruFocus
Biomarin Pharma earnings beat by $0.43, revenue topped estimates - Investing.com India
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Earnings call transcript: BioMarin beats Q1 2025 forecasts, stock rises after hours - Investing.com
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates - Nasdaq
BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets - Yahoo Finance
BMRN Q1 Revenue Surpasses Expectations with Strong Product Deman - GuruFocus
BioMarin: Q1 Earnings Snapshot - News-Times
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Rise - marketscreener.com
BioMarin Pharmaceutical Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) - Seeking Alpha
Biomarin Pharmaceutical Inc. Q1 Profit Increases, Beats Estimates - Nasdaq
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PR Newswire
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin Pharmaceutical Inc expected to post earnings of 71 cents a shareEarnings Preview - TradingView
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings - Barchart.com
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment? - simplywall.st
20 Takeover Rumors Hedge Funds Are Buying - Insider Monkey
BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo
Implied Volatility Surging for BioMarin Stock Options - Yahoo Finance
Oppenheimer maintains BioMarin stock Outperform with $98 target By Investing.com - Investing.com Nigeria
Oppenheimer maintains BioMarin stock Outperform with $98 target - Investing.com
Joshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - Longview News-Journal
BioMarin Earnings Preview: New CEO Alexander Hardy to Reveal First Quarter Strategy Shift - Stock Titan
Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction - Benzinga
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com
Quality Management Process LeadSan RafaelBioMarin Pharmaceutical - Ladders
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? - Yahoo Finance
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day - TradingView
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):